Test Directory
| Test Code | ||||||||||||||||||||||||||||||
| 1550 | ||||||||||||||||||||||||||||||
| Test Name | ||||||||||||||||||||||||||||||
| Fibrochondrogenesis 1 | ||||||||||||||||||||||||||||||
| CPT Codes | ||||||||||||||||||||||||||||||
| 81479 | ||||||||||||||||||||||||||||||
| Expected Turnaround Time | ||||||||||||||||||||||||||||||
| Typically 2 to 4 weeks from receipt of a sample in the laboratory. All cases involving ongoing pregnancies will be expedited. | ||||||||||||||||||||||||||||||
| Clinical Utility | ||||||||||||||||||||||||||||||
| Genetic analysis to provide a molecular diagnosis of this disorder. Recommended for individuals with a personal and/or family history of this disorder to ensure appropriate treatment and establish recurrence risk for family members. | ||||||||||||||||||||||||||||||
| Specimen and Container Info | ||||||||||||||||||||||||||||||
|
Non-Prenatal Specimens
Prenatal Specimens Either specimen type below is acceptable.
NOTE: For specimens from outside of North America, the preferred specimen type is Genomic DNA. HNL Genomics does not recommend shipping whole blood or cultured cells from any location other than the United States, Canada, or Mexico. |
||||||||||||||||||||||||||||||
| Transport Instructions | ||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
| Stability Requirements | ||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
| Causes for Rejection | ||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
| Methodology | ||||||||||||||||||||||||||||||
| Next Generation Sequencing and Copy Number Variation Analysis | ||||||||||||||||||||||||||||||
| Performing Location | ||||||||||||||||||||||||||||||
| Genomics - Snowdrift | ||||||||||||||||||||||||||||||
| Alternate Names | ||||||||||||||||||||||||||||||
| FBCG1 | ||||||||||||||||||||||||||||||
| Description | ||||||||||||||||||||||||||||||
|
Fibrochondrogenesis - Fibrochondrogenesis 1 (FBCG1; MIM 228520) and fibrochondrogenesis 2 (FBCG2; MIM 614524) are short limbed skeletal dysplasias that are usually, but not always lethal. The disorder is named for the disorganized cartilage growth plate in which chondrocytes resemble fibroblasts and there are regions of fibrous extracellular matrix. The patients have been described with frontal bossing, a flat mid face with a small nose, anteverted nares, long philtrum, cleft palate and short neck. The chest is small and bell shaped, the ribs are short and wide with metaphyseal cupping, the long bones are short with broad metaphyses, there is platyspondyly with posterior vertebral hypoplasia and a rounded anterior end, the pelvis may appear hypoplastic with small medial spikes. FBCG1 is caused by autosomal recessive mutations in COL11A1. FBCG2 is caused by either autosomal dominant or autosomal recessive mutations in COL11A2. Mutations in COL11A1 also cause Stickler syndrome, type II (STL2; MIM 604841) and Marshall syndrome (MIM 154780), which are autosomal dominant disorders characterized by facial dysmorphism, sensorineural hearing loss, high myopia, vitreoretinal degeneration and early onset arthritis. Mutations in COL11A2 cause Stickler syndrome, type III (STL3; MIM 184840), which is an autosomal dominant disorder similar to STL2 but lacking ocular findings. Mutations in COL11A2 also cause autosomal recessive otospondyloepimegaphyseal dysplasia (OSMED; MIM 215150) and autosomal dominant Weissenbacher-Zweymuller syndrome (WZS; MIM 277610). |
||||||||||||||||||||||||||||||
| Testing Schedule | ||||||||||||||||||||||||||||||
| Monday-Friday | ||||||||||||||||||||||||||||||
| Genes | ||||||||||||||||||||||||||||||
| COL11A1 | ||||||||||||||||||||||||||||||
| MIM | ||||||||||||||||||||||||||||||
| 228520 | ||||||||||||||||||||||||||||||
| Disease Group | ||||||||||||||||||||||||||||||
| Skeletal Disorders | ||||||||||||||||||||||||||||||
The American Medical Association (AMA) Current Procedural Terminology (CPT) codes published by HNL Lab Medicine are guidelines and are intended for informational purposes only. CPT coding is the exclusive responsibility of the billing entity. View the Terms.
© 2026 HNL Lab Medicine. All rights reserved.